Barclays’s Halozyme HALO Stock Holding History

Barclays’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Buy	+16,200	New	+$1.14M	﹤0.01%	2734
2020 Q1	–	Sell	-14,900	Closed	-$264K	–	6264
2019 Q4	$264K	Sell	14,900 -3,300	-18%	-$57.2K	﹤0.01%	4821
2019 Q3	$282K	Sell	18,200 -2,100	-10%	-$34.6K	﹤0.01%	4709
2019 Q2	$348K	Buy	20,300 +13,100	+182%	+$211K	﹤0.01%	4648
2019 Q1	$116K	Buy	7,200 +3,200	+80%	+$51.9K	﹤0.01%	5246
2018 Q4	$59K	Buy	+4,000	New	+$63.8K	﹤0.01%	5379
2018 Q2	–	Sell	-67,200	Closed	-$1.32M	–	7075
2018 Q1	$1.32M	Buy	67,200 +65,200	+3,260%	+$1.26M	﹤0.01%	2897
2017 Q4	$41K	Buy	+2,000	New	+$36.8K	﹤0.01%	5869
2017 Q3	–	Sell	-700	Closed	-$9K	–	6920
2017 Q2	$9K	Buy	+700	New	+$9.35K	﹤0.01%	6080
2015 Q1	–	Sell	-7,500	Closed	-$68K	–	7143
2014 Q4	$68K	Hold	7,500	–	–	﹤0.01%	5481
2014 Q3	$68K	Hold	7,500	–	–	﹤0.01%	5626
2014 Q2	$68K	Hold	7,500	–	–	﹤0.01%	5738
2014 Q1	$90K	Sell	7,500 -32,500	-81%	-$482K	﹤0.01%	5539
2013 Q4	$560K	Buy	40,000 +21,600	+117%	+$278K	﹤0.01%	3982
2013 Q3	$202K	Buy	+18,400	New	+$153K	﹤0.01%	5025

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's HALO Position: Q1 2026 in Review

Barclays reduced its Halozyme (HALO) stake by 18% in Q1 2026, selling an estimated $3.07M and leaving 193,242 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

Barclays first reported a position in HALO in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.6M in Q3 2025. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

Barclays held 193,242 shares of Halozyme worth $12.5M as of Q1 2026.
Barclays sold 43,522 Halozyme shares in Q1 2026, an estimated $3.07M.
Halozyme made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1331 holding.
Barclays first reported a position in Halozyme in Q2 2013 and has held it in 52 quarters since.
Barclays's Halozyme position peaked at $22.6M in Q3 2025.
635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.